NFE2L2 and amyotrophic lateral sclerosis: In the context of ALS marked by molecular heterogeneity, interplay between redox imbalance and RBP misregulation, and widespread nucleocytoplasmic disruption, Nrf2 activation holds appeal as a unifying therapeutic axis [69,93,102].